# ABCC Gene Variants and Their Effects on Non-Response and Relapse in Pediatric Patients with Central Nervous System Tumors: A Cohort Study

**Authors:** Luz María Torres-Espíndola, Juan Carlos Pérez-De Marcos, Manuel de Jesús Castillejos-López, Arnoldo Aquino-Gálvez, Liliana Velasco-Hidalgo, Rocío Cárdenas-Cardós, Armando De Uña-Flores, Marta Zapata-Tarrés, Anjartah Higuera-Iglesias

PMC · DOI: 10.3390/cimb48020205 · 2026-02-13

## TL;DR

This study finds that specific genetic variants in ABCC1 and ABCC2 genes are linked to poor treatment response and higher relapse risk in children with brain tumors.

## Contribution

The study identifies novel associations between ABCC1 and ABCC2 gene variants and clinical outcomes in pediatric CNS tumor patients.

## Key findings

- ABCC1 r.5540 G>C variant is significantly associated with non-response and relapse in pediatric CNS tumor patients.
- ABCC2 c.3972 C>T variant is significantly linked to relapse in a recessive model.
- Multivariate analysis confirms the predictive value of these SNVs after adjusting for age and sex.

## Abstract

The variability in outcomes among individuals is caused by multiple factors, including genetic variations in drug transporter genes known as ABCs. This study investigates the clinical effect of single-nucleotide variants (SNVs) in the ABCC1/MRP1, ABCC2/MRP2, and ABCC4/MRP4 genes on the clinical response and relapse of pediatric patients with central nervous system tumors. In a cohort-based association study involving 111 cancer patients, genotyping of ABCC1/MRP1, ABCC2/MRP2, and ABCC4/MRP4 was conducted using real-time PCR with TaqMan probes. Treatment response was evaluated using the Response Assessment in Neuro-Oncology (RANO) criteria. Univariate and multivariate analyses were conducted using the Cox proportional hazards (adjusted) model. Multivariate analysis adjusted for sex and age showed a significant association between ABCC1 r.5540out G>C; rs12921623 in the gene and non-response to treatment in the codominant model [HR] 2.095, 95% CI 1.202–3.650, p = 0.009, and in the dominant model [HR] 2.025, 95% CI 1.199–3.421, p = 0.008, and an increased risk of relapse in the codominant model [HR] 9.09, 95% CI 1.04–78.85, p = 0.04, and in the dominant model [HR] 3.912, 95% CI 1.139–13.436, p = 0.03. Furthermore, a significant association was found between ABCC2 c. 3972 C>T; rs3740066 and relapse in the recessive model [HR] 3.5, 95% CI 1.02–12.17, p = 0.04. Our findings indicate that ABCC1 r.5540 G>C SNV and ABCC2 c. 3972 C>T SNV are significant predictors of non-response and relapse in this group of pediatric patients with central nervous system tumors.

## Linked entities

- **Genes:** ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) [NCBI Gene 4363], CD9 (CD9 molecule) [NCBI Gene 928], ABCC2 (ATP binding cassette subfamily C member 2) [NCBI Gene 1244], ABCC2 (ATP binding cassette subfamily C member 2) [NCBI Gene 1244], ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257], ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257]

## Full-text entities

- **Genes:** ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group)) [NCBI Gene 9429] {aka ABC15, ABCP, BCRP, BMDP, CD338, CDw338}, ABCC2 (ATP binding cassette subfamily C member 2) [NCBI Gene 1244] {aka ABC30, CMOAT, DJS, MRP2, cMRP}, ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257] {aka MOAT-B, MOATB, MRP4}, ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) [NCBI Gene 4363] {aka ABC29, ABCC, DFNA77, GS-X, MRP, MRP1}
- **Diseases:** cytotoxic (MESH:D064420), Central Nervous System Tumors (MESH:D016543), colorectal neoplasms (MESH:D015179), epilepsy (MESH:D004827), breast cancer (MESH:D001943), lung cancer (MESH:D008175), neurotoxicity (MESH:D020258), cancer (MESH:D009369), MDR (MESH:D018088), pancreatic cancer (MESH:D010190), injury to (MESH:D014947), osteosarcoma (MESH:D012516), gliomas (MESH:D005910), medulloblastoma (MESH:D008527), ependymomas (MESH:D004806), sarcomas (MESH:D012509), psoriasis (MESH:D011565), Nervous System Tumor (MESH:D009423)
- **Chemicals:** Etoposide (MESH:D005047), Temozolomide (MESH:D000077204), Actinomycin D (MESH:D003609), Carboplatin (MESH:D016190), carboplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, cisplatin (-), Cisplatin (MESH:D002945), ICE (MESH:D007053), agarose (MESH:D012685), Ifosfamide (MESH:D007069), Vincristine (MESH:D014750), anthracyclines (MESH:D018943), Cyclophosphamide (MESH:D003520), fluorouracil (MESH:D005472), methotrexate (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G>C, r.5540 G>C, G671V, G1249A, r.5522 G>A, rs1059751, r.5540 G>C, rs3742106, p.Leu562Leu, rs4148551, G>C, r.1658 G>T, c. 3972 C>T

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939642/full.md

---
Source: https://tomesphere.com/paper/PMC12939642